无限的可乐
Lv5
1140 积分
2023-07-18 加入
-
Comparative safety of oral Janus kinase inhibitors and dupilumab in patients with atopic dermatitis: a population-based cohort study
2天前
已完结
-
特应性皮炎的全程管理共识
2天前
已完结
-
The efficacy and safety of JAK inhibitors in patients with adult-onset still's disease: A meta-analysis and systematic review
3天前
已完结
-
Trends in atopic dermatitis prevalence among the Chinese population (1990–2021) with projections for 2022–2030
5天前
已完结
-
抗风湿药物胃肠道损伤管理中国专家共识(2024版)
17天前
已完结
-
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
20天前
已完结
-
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
20天前
已关闭
-
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4)
23天前
已完结
-
Regulation of the JAK/STAT signaling pathway: The promising targets for cardiovascular disease
28天前
已完结
-
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
28天前
已完结